LIDDS to evaluate a possible listing of the company’s shares on Nasdaq Stockholm’s Main Market during 2020

NEXT STORY
TLC Announces First Patient Dosed in Phase II Trial of TLC590 for Postsurgical Pain Management following Bunionectomy
PREV STORY
New Clinical Trial Shows Medtronic TYRX(TM) Envelope Signficantly Reduces Major Infections in Cardiac Implantable Device Patients
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Basilea berichtet über Präsentationen zu Isavuconazol (Cresemba®) und Ceftobiprol (Zevtera®) auf dem Europäischen Kongress für Klinische Mikrobiologie und Infektionskrankheiten (ECCMID)

author_avatar
NASDAQ Market News

ContraFect’s New Phase 2 Exebacase Data Presented at IDWeekTM Demonstrates Rapid Symptom Resolution Among Patients with Staphylococcus aureus Bacteremia

author_avatar
NASDAQ Market News

Jounce Therapeutics Reports First Quarter 2021 Financial Results

author_avatar
NASDAQ Market News